^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KRAS mutation

    i
    Other names: KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
    Entrez ID:
    3845
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    17h
    Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Sichuan University
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    oxaliplatin
    19h
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations (clinicaltrials.gov)
    P1/2, N=178, Recruiting, Shenzhen Ionova Life Sciences Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    19h
    Delayed Endobronchial Metastasis of Colorectal Adenocarcinoma Five Years After Resection: A Case Report. (PubMed, Cureus)
    Furthermore, loss to follow-up in high-risk patients may permit undetected disease progression, supporting a more individualized approach to long-term surveillance. Imaging alone may fail to detect endobronchial disease, making early bronchoscopy essential for timely diagnosis and management.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CDX2 (Caudal Type Homeobox 2)
    |
    KRAS mutation
    19h
    Synchronous metastatic differentiated high-grade thyroid carcinoma in lymph node from classic papillary thyroid carcinoma: a case report and literature review. (PubMed, Front Oncol)
    Genetic testing of the PMs revealed no mutations in BRAF, KRAS, or NRAS, and no RET rearrangement. The patient's condition was subsequently managed with targeted therapy and immunotherapy, which achieved disease stabilization.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RET rearrangement
    20h
    3082-CL-0301: A study to confirm the safety of ASP3082, and if it delays tumor growth in people with pancreatic cancer, when given with either mFOLFIRINOX or NALIRIFOX chemotherapies (2025-523684-38-00)
    P2/3, N=35, Not yet recruiting, Astellas Pharma Global Development Inc.
    New P2/3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • setidegrasib (ASP3082) • Onivyde (nanoliposomal irinotecan)
    20h
    VS-7375-101: A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors (2025-523432-39-01)
    P1/2, N=120, Not yet recruiting, Verastem Inc.
    New P1/2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • RET (Ret Proto-Oncogene)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • albumin-bound paclitaxel • pemetrexed
    20h
    GS-US-741-7756: Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer. (2025-523984-39-00)
    P1/2, N=75, Not yet recruiting, Gilead Sciences Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • RAS wild-type • KRAS G12
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • denikitug (GS-1811)
    20h
    The Efficacy of Tislelizumab Combined With Albumin-bound Paclitaxel and Platinum-based Chemotherapy in Patients With KRAS-mutated Lung Cancer (clinicaltrials.gov)
    P=N/A, N=30, Active, not recruiting, Guangzhou Medical University
    New trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    21h
    A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations (clinicaltrials.gov)
    P1, N=448, Recruiting, Alterome Therapeutics, Inc. | N=188 --> 448
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • midazolam hydrochloride
    21h
    Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses. (PubMed, Clin Cancer Res)
    KRAS Q61H and Q61L were the predominant mutational subtypes and demonstrated distinct molecular and clinical characteristics, with differences in co-mutational landscape and survival differences. Immunotherapy-based regimens were associated with more favorable outcomes compared to chemotherapy, particularly in patients with high PD-L1 expression, underscoring the importance of subtype-specific molecular characterization in clinical decision-making.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
    |
    PD-L1 expression • TP53 mutation • KRAS mutation • PD-L1 overexpression • STK11 mutation • KEAP1 mutation • KRAS Q61
    22h
    Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, UNC Lineberger Comprehensive Cancer Center
    New P2 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • olomorasib (LY3537982)
    23h
    CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (clinicaltrials.gov)
    P3, N=450, Recruiting, Amgen | Trial completion date: Aug 2031 --> Apr 2032 | Trial primary completion date: Jan 2028 --> Sep 2028
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • Lumakras (sotorasib) • irinotecan • leucovorin calcium • Mvasi (bevacizumab-awwb)